Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Caspofungin in Invasive Aspergillosis
NCT00110045Phase 2Completed
- Sponsor
- European Organisation for Research and Treatment of Cancer
- Start
- Feb 2005
- Primary completion
- Mar 2008
- Modality
- Cyclic Peptides, Antimicrobial Peptides, Small Molecules
- Countries
- 7
01
Overview
A Phase 2 trial of caspofungin in invasive aspergillosis (IA), sponsored by European Organisation for Research and Treatment of Cancer. Started Feb 2005; status: completed.
02
Drugs
caspofungin
03
Conditions
invasive aspergillosis (IA)
Beyond the preview
Go deeper on NCT00110045.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00110045.